Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Accelerating Leigh syndrome drug discovery through deep learning screening in brain organoids

  • Menacho, Carmen
  • Okawa, Satoshi
  • Álvarez-Merz, Iris
  • Wittich, Annika
  • Muñoz-Oreja, Mikel
  • Lisowski, Pawel
  • López Martín, Mario
  • Pentimalli, Tancredi Massimo
  • Zakin, Shiri
  • Thevandavakkam, Mathuravani
  • Jerred, Caleb
  • Lickfett, Selene
  • Petersilie, Laura
  • Rybak-Wolf, Agnieszka
  • Seibt, Annette
  • Herebian, Diran
  • Inak, Gizem
  • Brodesser, Susanne
  • Zaliani, Andrea
  • Mlody, Barbara
  • Donnelly, Justin
  • Woleben, Kasey
  • Soriano, Francesc Xavier
  • Fernández-Checa, José C.
  • Ventura, Natascia
  • Cambridge, Sidney
  • Mayatepek, Ertan
  • Spinazzola, Antonella
  • Schuelke, Markus
  • Rajewsky, Nikolaus
  • Rossi, Andrea
  • Peralvarez-Marin, Alex
  • Distelmaier, Felix
  • Perlstein, Ethan
  • Holt, Ian J.
  • Puighermanal, Emma
  • Pless, Ole
  • Rose, Christine R.
  • Del Sol, Antonio
  • Prigione, Alessandro
Leigh syndrome (Leigh) is an untreatable mitochondrial disorder characterized by lactic acidosis and basal ganglia and midbrain pathology, leading to psychomotor regression and early death. We previously uncovered impaired neuronal morphogenesis in Leigh cerebral organoids carrying SURF1 gene variants. Leveraging this phenotype, we here develop a deep learning algorithm tailored for cell type-specific drug repurposing screening. In parallel, we perform a survival drug screen in a yeast model of Leigh. The two approaches independently converge on azole compounds, two of which - talarozole and sertaconazole - rescue neuronal morphogenesis in Leigh neurons and lower lactate release and improve growth rate in Leigh midbrain organoids. Mechanistically, these compounds modulate the retinoic acid pathway and membrane-associate lipid metabolism. The findings highlight azoles as promising candidates for Leigh and demonstrate the potential of combining in silico screens with human brain organoids as new approach methodologies (NAMs) to advance the discovery of therapeutics addressing rare neurodevelopmental disorders., Open Access funding enabled and organized by Projekt DEAL. We thank Jens Schwamborn (Luxembourg University) and his group for providing their published MO datasets. We acknowledge support from the Deutsche Forschungsgemeinschaft (DFG) (PR1527/5-1, PR1527/6-1, PR1527/15-1, PR1527/14-1, and PR1527/13-1 to A.P.; RO5380/1-1 to A.R.; Ro2327/13-2 to C.R.R.; AL2956/1-1 to I.A-M.; VE366/12-1 to N.V.), the European Joint Programme on Rare Diseases (EJP RD) and Federal Ministry of Research, Technology and Space (BMFTR) (CureMILS #01GM2002A to A.P., #01GM2002B to O.P.), the Medical Faculty of Heinrich Heine University (FoKo grant to A.P. and S.C.), the European Commission’s Horizon Europe Programme (SIMPATHIC #101080249 to A.P. and M.S.), AFM-Téléthon (SildeMITO #28545 to A.P. and M.S.; GenT-Leigh #29044 to A.P.), the United Mitochondrial Disease Foundation (UMDF) and the Leigh Syndrome International Consortium (LSIC) (to A.P.), People Against Leigh syndrome (PALS) (to A.P.), the Foundation Maladies Rare and Association (AMMi) (to A.P.), the patient organizations Mitocon, Cure Mito, Cure ATP6, Mito Foundation, and MitoHelp (to A.P.), and the Eva Luise Köhler Foundation (to A.P. and M.S.), the Studienstiftung des deutschen Volkes (to S.L.), the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGUAR) Generalitat de Catalunya through the Indústria del Coneixement LLAVOR program (grant 2024 LLAV 00069 to E.Pu.), National Science Center OPUS (#2017/27/B/NZ1/02401 to P.L.), and funds from MICINN (PID2021-125079OA-I00 to E.Pu.). A.Sp. and I.J.H. receive research support from the UK Medical Research Council (MR/X002365/1), Muscular Dystrophy UK (17GRO-PG24-0184-1), and the CHAMP Foundation. A.Sp. is the recipient of a Miriam Marks Senior Fellowship, Brain Research UK (202021-26) and receives funds from the Lily Foundation. I.J.H. is supported by grants from the Instituto de Salud Carlos III PI20/00096, the Spanish Ministry of Science, PID2023-151649NB-I00, and the Basque Government Department of Health (Osasun Saila, Eusko Jaurlaritzako) (grants 2021111070; 2022333050; 2018111043; 2018222031). M.M.O. was partially supported by the Ikerbasque, Basque Foundation for Science IKUR strategy, Neurodegenprot project. S.L. was supported by the Studienstiftung des deutschen Volkes. J.F-C acknowledges support from the MICINN (PID2022-142956OB-100 and PID2025-173094OB-I00), the National Cancer Institute PO1 CA281819-O1A1 from the NIH, and the CIBEREHD and the European Horizon´s research and Innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement #101095679). We are grateful to Anje Sporbert (Advanced Light Microscopy, MDC, Berlin) for help with the mitochondrial movement recordings and acknowledge the Center for Advanced Imaging (CAi) at Heinrich Heine University Düsseldorf for providing access to the PerkinElmer Operetta CLS (DFG grant # INST 208/760-1 FUGG) and Olympus FV3000 microscope., Peer reviewed